Navitoclax-piperazine

Navitoclax-piperazine

• CAS Number: 2143096-93-7
• UNSPSC Description: Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604) with anti-tumor activity[1].
• Target Antigen: Bcl-2 Family; Ligands for Target Protein for PROTAC
• Type: Reference compound
• Related Pathways: Apoptosis;PROTAC
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/navitoclax-piperazine.html
• Purity: 99.73
• Solubility: DMSO : 125 mg/mL (ultrasonic)
• Smiles: O=C(NS(=O)(C1=CC=C(N[C@@H](CSC2=CC=CC=C2)CCN3CCNCC3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
• Molecular Weight: 973.63
• References & Citations: [1]Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019).
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported